Pharmacosmos Group Acquires G1 Therapeutics in $405 Million Deal

Pharmacosmos Group has announced its acquisition of G1 Therapeutics Inc. for $405 million. Shareholders of G1 Therapeutics will receive $7.15 per share in cash. The deal is fully financed by Pharmacosmos' existing cash reserves and credit facilities.

Pharmacosmos Group has confirmed the acquisition of G1 Therapeutics Inc. for a total of $405 million. This strategic move will have significant ramifications in the pharmaceutical industry.

Under the terms of the agreement, G1 Therapeutics' shareholders are set to receive $7.15 per share in cash. The transaction values the total equity at approximately $405 million.

The deal is entirely financed through Pharmacosmos' existing cash reserves and available credit facilities, ensuring a smooth financial transition. This acquisition underscores Pharmacosmos' commitment to expanding its footprint in the oncology sector.